Investing 391 Million Yuan: Weiing Health Grants Equity Incentives of 95 Million Shares for the First Time, Benefiting 547 Key Employees

On March 16, Weining Health (300253) announced that the conditions for the first grant of its 2026 restricted stock incentive plan have been met. On the same day, 9.5 million second-class restricted shares were granted at a price of 5.32 yuan per share to 547 incentive recipients, accounting for 4.29% of the company’s current total share capital. The estimated total amortization expense is 391 million yuan, which will be used to supplement the company’s working capital.

Originally, the plan intended to grant 9.6 million shares to 703 recipients. Due to 156 recipients voluntarily waiving part or all of their allocated shares, the final grant was adjusted to 547 recipients receiving 9.5 million shares, with 4 million shares reserved for future grants. The incentive targets include the company’s directors, senior management, middle management, core technical (business) personnel, and foreign employees. Among them, President Wang Tao was granted 2.4 million shares, and a total of 87.96 million shares were granted to 542 middle management and core personnel, representing 88.85% of the initial grant.

The performance assessment rules specify that the plan’s maximum validity period is 72 months. The initial grant vests in four phases after 12 months from the grant date, with vesting proportions of 35%, 25%, 20%, and 20%. The company has set clear performance targets: from 2026 to 2029, the net profit attributable to shareholders (excluding non-recurring gains and losses and share-based payment expenses) must be no less than 80 million yuan, 180 million yuan, 300 million yuan, and 500 million yuan, respectively. On an individual level, vesting is determined by assessment levels at 100%, 70%, or 0%.

Financially, the 391 million yuan amortization expense will be recognized over 2026-2030 as follows: 171 million yuan, 129 million yuan, 59 million yuan, 27 million yuan, and 5 million yuan. The company states that this incentive plan will deeply align the interests of shareholders, the company, and employees, enhance team stability and motivation, and support the company’s continued expansion in the medical informatization field. The expected performance improvements from the incentive are anticipated to offset the impact of the expense amortization.

In the first three quarters of 2025, Weining Health achieved revenue of 1.296 billion yuan, with a net loss attributable to shareholders of 241 million yuan.